Energenesis Biomedical CoTPE:6657 +4.94%63 Current Ratio is 19.91 as of Dec. 2025, which is 12% below its 10-year median of 22.50. GuruFocus rates TPE:6657 with a GF Score™ of 63/100 and a GF Value™ of NT$51.34 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Energenesis Biomedical Co ranks better than 92.13% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Energenesis Biomedical Co's current ratio for the quarter that ended in Dec. 2025 was 19.91.
Energenesis Biomedical Co has a current ratio of 19.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Energenesis Biomedical Co's Current Ratio or its related term are showing as below:
TPE:6657'
s Current Ratio Range Over the Past 10 Years
Min: 8.2 Med: 22.5 Max: 36.03
Current: 19.91
During the past 11 years, Energenesis Biomedical Co's highest Current Ratio was 36.03. The lowest was 8.20. And the median was 22.50.
TPE:6657's Current Ratio is ranked better than 92.13% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs TPE:6657: 19.91
Energenesis Biomedical Co (TPE:6657) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Energenesis Biomedical Co Current Ratio Related Terms
Energenesis Biomedical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6657 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Energenesis Biomedical Co (TPE:6657) has a Current Ratio of 19.91 as of Dec. 2025. This is 12% below median its historical median of 22.50. Over the past decade, Energenesis Biomedical Co's Current Ratio has ranged from 8.20 to 36.03. According to the industry distribution chart, Energenesis Biomedical Co ranks #111 out of 1411 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Energenesis Biomedical Co's Current Ratio too high?
Energenesis Biomedical Co's current Current Ratio of 19.91 is 12% below median its 10-year median of 22.50. Over the past 10 years, this metric has ranged from a low of 8.20 to a high of 36.03. The Biotechnology industry median Current Ratio is 3.91. Energenesis Biomedical Co's value of 19.91 is 409.2% above this industry median. Based on the distribution chart, Energenesis Biomedical Co ranks #111 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Energenesis Biomedical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #111 out of 1411 companies for Current Ratio. This places Energenesis Biomedical Co in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.91. Energenesis Biomedical Co's value of 19.91 is 409.2% above this benchmark. Historically, Energenesis Biomedical Co's own Current Ratio has ranged from 8.20 to 36.03 over the past decade. While the company's 10-year median is 22.50 vs. the industry median of 3.91, Energenesis Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Energenesis Biomedical Co's current Current Ratio of 19.91 is 409.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current Current Ratio is 19.91, which is 12% below median its own 10-year median of 22.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.34, compared to a current price of NT$37.15 — trading 27.6% below its estimated fair value. The current Current Ratio is 19.91, which is 12% below median its 10-year median of 22.50 and 409.2% above the Biotechnology industry median of 3.91. Energenesis Biomedical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Current Ratio is 19.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$37.15 is trading 27.6% below its estimated GF Value™ of NT$51.34.
GuruFocus considers Energenesis Biomedical Co to be Modestly Undervalued.
Key valuation signals for TPE:6657:
Current Ratio: 19.91 (12% below median its 10-year median of 22.50)
GF Value™: NT$51.34 vs. price of NT$37.15 (27.6% below fair value)
Industry Position: 409.2% above the Biotechnology median (#111 of 1411)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
63GF Score
Get the complete analysis for TPE:6657
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
